nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—ABL1—Regulation of retinoblastoma protein—MITF—vascular cancer	0.0255	0.0255	CbGpPWpGaD
Afatinib—ERBB2—Validated targets of C-MYC transcriptional repression—TSC2—vascular cancer	0.0218	0.0218	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways in Glioblastoma—TSC2—vascular cancer	0.0177	0.0177	CbGpPWpGaD
Afatinib—ERBB2—Constitutive PI3K/AKT Signaling in Cancer—TSC2—vascular cancer	0.017	0.017	CbGpPWpGaD
Afatinib—ERBB4—Constitutive PI3K/AKT Signaling in Cancer—TSC2—vascular cancer	0.0167	0.0167	CbGpPWpGaD
Afatinib—ERBB2—PI-3K cascade—TSC2—vascular cancer	0.0153	0.0153	CbGpPWpGaD
Afatinib—ERBB4—PI-3K cascade—TSC2—vascular cancer	0.0151	0.0151	CbGpPWpGaD
Afatinib—ERBB2—PI3K/AKT activation—TSC2—vascular cancer	0.0149	0.0149	CbGpPWpGaD
Afatinib—ERBB2—GAB1 signalosome—TSC2—vascular cancer	0.0148	0.0148	CbGpPWpGaD
Afatinib—ERBB4—PI3K/AKT activation—TSC2—vascular cancer	0.0147	0.0147	CbGpPWpGaD
Afatinib—ERBB4—GAB1 signalosome—TSC2—vascular cancer	0.0146	0.0146	CbGpPWpGaD
Afatinib—ERBB2—Role of LAT2/NTAL/LAB on calcium mobilization—TSC2—vascular cancer	0.0145	0.0145	CbGpPWpGaD
Afatinib—ERBB4—Role of LAT2/NTAL/LAB on calcium mobilization—TSC2—vascular cancer	0.0143	0.0143	CbGpPWpGaD
Afatinib—PHKG2—Disease—WWTR1—vascular cancer	0.0137	0.0137	CbGpPWpGaD
Afatinib—PHKG2—Metabolism—WWTR1—vascular cancer	0.0115	0.0115	CbGpPWpGaD
Afatinib—ERBB2—Signaling by SCF-KIT—TSC2—vascular cancer	0.0114	0.0114	CbGpPWpGaD
Afatinib—ERBB4—Signaling by SCF-KIT—TSC2—vascular cancer	0.0113	0.0113	CbGpPWpGaD
Afatinib—ERBB2—Downstream signaling of activated FGFR—TSC2—vascular cancer	0.011	0.011	CbGpPWpGaD
Afatinib—ERBB4—Downstream signaling of activated FGFR—TSC2—vascular cancer	0.0108	0.0108	CbGpPWpGaD
Afatinib—ERBB2—Signaling by ERBB4—TSC2—vascular cancer	0.0108	0.0108	CbGpPWpGaD
Afatinib—ERBB4—Signaling by ERBB4—TSC2—vascular cancer	0.0106	0.0106	CbGpPWpGaD
Afatinib—ERBB2—Downstream signal transduction—TSC2—vascular cancer	0.0103	0.0103	CbGpPWpGaD
Afatinib—ERBB2—Signaling by FGFR—TSC2—vascular cancer	0.0102	0.0102	CbGpPWpGaD
Afatinib—ERBB2—Signaling by ERBB2—TSC2—vascular cancer	0.0102	0.0102	CbGpPWpGaD
Afatinib—ERBB2—DAP12 signaling—TSC2—vascular cancer	0.0101	0.0101	CbGpPWpGaD
Afatinib—ERBB4—Downstream signal transduction—TSC2—vascular cancer	0.0101	0.0101	CbGpPWpGaD
Afatinib—ERBB4—Signaling by FGFR—TSC2—vascular cancer	0.0101	0.0101	CbGpPWpGaD
Afatinib—ERBB4—Signaling by ERBB2—TSC2—vascular cancer	0.01	0.01	CbGpPWpGaD
Afatinib—ERBB2—Downstream signaling events of B Cell Receptor (BCR)—TSC2—vascular cancer	0.01	0.01	CbGpPWpGaD
Afatinib—ERBB4—DAP12 signaling—TSC2—vascular cancer	0.00999	0.00999	CbGpPWpGaD
Afatinib—ERBB4—Downstream signaling events of B Cell Receptor (BCR)—TSC2—vascular cancer	0.00985	0.00985	CbGpPWpGaD
Afatinib—ERBB2—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	0.00954	0.00954	CbGpPWpGaD
Afatinib—ERBB2—Signaling by FGFR in disease—TSC2—vascular cancer	0.00954	0.00954	CbGpPWpGaD
Afatinib—ERBB2—DAP12 interactions—TSC2—vascular cancer	0.00954	0.00954	CbGpPWpGaD
Afatinib—ERBB2—Signaling by EGFR—TSC2—vascular cancer	0.00946	0.00946	CbGpPWpGaD
Afatinib—ERBB4—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	0.0094	0.0094	CbGpPWpGaD
Afatinib—ERBB4—Signaling by FGFR in disease—TSC2—vascular cancer	0.0094	0.0094	CbGpPWpGaD
Afatinib—ERBB4—DAP12 interactions—TSC2—vascular cancer	0.0094	0.0094	CbGpPWpGaD
Afatinib—ERBB2—Signaling by EGFR in Cancer—TSC2—vascular cancer	0.00937	0.00937	CbGpPWpGaD
Afatinib—ERBB2—Signaling by PDGF—TSC2—vascular cancer	0.00933	0.00933	CbGpPWpGaD
Afatinib—ERBB4—Signaling by EGFR—TSC2—vascular cancer	0.00932	0.00932	CbGpPWpGaD
Afatinib—ERBB4—Signaling by EGFR in Cancer—TSC2—vascular cancer	0.00923	0.00923	CbGpPWpGaD
Afatinib—ERBB4—Signaling by PDGF—TSC2—vascular cancer	0.00919	0.00919	CbGpPWpGaD
Afatinib—ERBB2—B Cell Activation—TSC2—vascular cancer	0.00883	0.00883	CbGpPWpGaD
Afatinib—ERBB4—B Cell Activation—TSC2—vascular cancer	0.0087	0.0087	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways in Glioblastoma—TSC2—vascular cancer	0.00854	0.00854	CbGpPWpGaD
Afatinib—ERBB2—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.00845	0.00845	CbGpPWpGaD
Afatinib—BLK—B Cell Activation—TSC2—vascular cancer	0.00837	0.00837	CbGpPWpGaD
Afatinib—ERBB4—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.00833	0.00833	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—CD34—vascular cancer	0.00822	0.00822	CbGpPWpGaD
Afatinib—EGFR—Constitutive PI3K/AKT Signaling in Cancer—TSC2—vascular cancer	0.00822	0.00822	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—CD34—vascular cancer	0.0081	0.0081	CbGpPWpGaD
Afatinib—LCK—Constitutive PI3K/AKT Signaling in Cancer—TSC2—vascular cancer	0.00792	0.00792	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—CD34—vascular cancer	0.00779	0.00779	CbGpPWpGaD
Afatinib—EGFR—PI-3K cascade—TSC2—vascular cancer	0.0074	0.0074	CbGpPWpGaD
Afatinib—EGFR—PI3K/AKT activation—TSC2—vascular cancer	0.00723	0.00723	CbGpPWpGaD
Afatinib—EGFR—GAB1 signalosome—TSC2—vascular cancer	0.00717	0.00717	CbGpPWpGaD
Afatinib—LCK—PI-3K cascade—TSC2—vascular cancer	0.00713	0.00713	CbGpPWpGaD
Afatinib—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—TSC2—vascular cancer	0.00701	0.00701	CbGpPWpGaD
Afatinib—LCK—PI3K/AKT activation—TSC2—vascular cancer	0.00696	0.00696	CbGpPWpGaD
Afatinib—LCK—GAB1 signalosome—TSC2—vascular cancer	0.00691	0.00691	CbGpPWpGaD
Afatinib—ERBB2—Disease—WWTR1—vascular cancer	0.00681	0.00681	CbGpPWpGaD
Afatinib—LCK—Role of LAT2/NTAL/LAB on calcium mobilization—TSC2—vascular cancer	0.00675	0.00675	CbGpPWpGaD
Afatinib—ERBB4—Disease—WWTR1—vascular cancer	0.00671	0.00671	CbGpPWpGaD
Afatinib—ERBB2—Signaling by NGF—TSC2—vascular cancer	0.0065	0.0065	CbGpPWpGaD
Afatinib—PHKG2—Metabolism—HBA1—vascular cancer	0.00644	0.00644	CbGpPWpGaD
Afatinib—ERBB4—Signaling by NGF—TSC2—vascular cancer	0.0064	0.0064	CbGpPWpGaD
Afatinib—ABL1—Integrated Breast Cancer Pathway—TSC2—vascular cancer	0.00613	0.00613	CbGpPWpGaD
Afatinib—EGFR—Direct p53 effectors—TSC2—vascular cancer	0.00557	0.00557	CbGpPWpGaD
Afatinib—EGFR—Signaling by SCF-KIT—TSC2—vascular cancer	0.00553	0.00553	CbGpPWpGaD
Afatinib—LCK—Signaling by SCF-KIT—TSC2—vascular cancer	0.00533	0.00533	CbGpPWpGaD
Afatinib—EGFR—Downstream signaling of activated FGFR—TSC2—vascular cancer	0.00529	0.00529	CbGpPWpGaD
Afatinib—EGFR—Integrated Breast Cancer Pathway—TSC2—vascular cancer	0.00524	0.00524	CbGpPWpGaD
Afatinib—EGFR—Signaling by ERBB4—TSC2—vascular cancer	0.00521	0.00521	CbGpPWpGaD
Afatinib—LCK—Downstream signaling of activated FGFR—TSC2—vascular cancer	0.0051	0.0051	CbGpPWpGaD
Afatinib—LCK—Signaling by ERBB4—TSC2—vascular cancer	0.00502	0.00502	CbGpPWpGaD
Afatinib—ERBB2—Immune System—CD34—vascular cancer	0.00499	0.00499	CbGpPWpGaD
Afatinib—EGFR—Downstream signal transduction—TSC2—vascular cancer	0.00498	0.00498	CbGpPWpGaD
Afatinib—EGFR—Signaling by FGFR—TSC2—vascular cancer	0.00495	0.00495	CbGpPWpGaD
Afatinib—EGFR—Signaling by ERBB2—TSC2—vascular cancer	0.00493	0.00493	CbGpPWpGaD
Afatinib—ERBB4—Immune System—CD34—vascular cancer	0.00491	0.00491	CbGpPWpGaD
Afatinib—EGFR—DAP12 signaling—TSC2—vascular cancer	0.0049	0.0049	CbGpPWpGaD
Afatinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—TSC2—vascular cancer	0.00483	0.00483	CbGpPWpGaD
Afatinib—LCK—Downstream signal transduction—TSC2—vascular cancer	0.0048	0.0048	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—WWTR1—vascular cancer	0.00477	0.00477	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR—TSC2—vascular cancer	0.00477	0.00477	CbGpPWpGaD
Afatinib—LCK—Signaling by ERBB2—TSC2—vascular cancer	0.00475	0.00475	CbGpPWpGaD
Afatinib—LCK—DAP12 signaling—TSC2—vascular cancer	0.00473	0.00473	CbGpPWpGaD
Afatinib—BLK—Immune System—CD34—vascular cancer	0.00472	0.00472	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—WWTR1—vascular cancer	0.0047	0.0047	CbGpPWpGaD
Afatinib—IRAK1—Signaling by NGF—TSC2—vascular cancer	0.0047	0.0047	CbGpPWpGaD
Afatinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—TSC2—vascular cancer	0.00466	0.00466	CbGpPWpGaD
Afatinib—EGFR—Signaling by FGFR in disease—TSC2—vascular cancer	0.00461	0.00461	CbGpPWpGaD
Afatinib—EGFR—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	0.00461	0.00461	CbGpPWpGaD
Afatinib—EGFR—DAP12 interactions—TSC2—vascular cancer	0.00461	0.00461	CbGpPWpGaD
Afatinib—EGFR—Signaling by EGFR—TSC2—vascular cancer	0.00457	0.00457	CbGpPWpGaD
Afatinib—EGFR—Signaling by EGFR in Cancer—TSC2—vascular cancer	0.00453	0.00453	CbGpPWpGaD
Afatinib—EGFR—Signaling by PDGF—TSC2—vascular cancer	0.00451	0.00451	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR in disease—TSC2—vascular cancer	0.00445	0.00445	CbGpPWpGaD
Afatinib—LCK—DAP12 interactions—TSC2—vascular cancer	0.00445	0.00445	CbGpPWpGaD
Afatinib—LCK—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	0.00445	0.00445	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR—TSC2—vascular cancer	0.00441	0.00441	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR in Cancer—TSC2—vascular cancer	0.00437	0.00437	CbGpPWpGaD
Afatinib—LCK—Signaling by PDGF—TSC2—vascular cancer	0.00435	0.00435	CbGpPWpGaD
Afatinib—EGFR—B Cell Activation—TSC2—vascular cancer	0.00427	0.00427	CbGpPWpGaD
Afatinib—LCK—B Cell Activation—TSC2—vascular cancer	0.00411	0.00411	CbGpPWpGaD
Afatinib—EGFR—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.00409	0.00409	CbGpPWpGaD
Afatinib—PHKG2—Disease—TSC2—vascular cancer	0.00402	0.00402	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—CD34—vascular cancer	0.00397	0.00397	CbGpPWpGaD
Afatinib—LCK—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.00394	0.00394	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CD34—vascular cancer	0.00383	0.00383	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—TSC2—vascular cancer	0.00371	0.00371	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—TSC2—vascular cancer	0.00365	0.00365	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CD34—vascular cancer	0.0036	0.0036	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—TSC2—vascular cancer	0.00356	0.00356	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—TSC2—vascular cancer	0.00351	0.00351	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—WWTR1—vascular cancer	0.00345	0.00345	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—TSC2—vascular cancer	0.00337	0.00337	CbGpPWpGaD
Afatinib—EGFR—Disease—WWTR1—vascular cancer	0.00329	0.00329	CbGpPWpGaD
Afatinib—LCK—Disease—WWTR1—vascular cancer	0.00317	0.00317	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—TSC2—vascular cancer	0.00314	0.00314	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—TSC2—vascular cancer	0.00303	0.00303	CbGpPWpGaD
Afatinib—ABL1—Immune System—CD34—vascular cancer	0.00282	0.00282	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—TSC2—vascular cancer	0.00268	0.00268	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—WWTR1—vascular cancer	0.00258	0.00258	CbGpPWpGaD
Afatinib—EGFR—Immune System—CD34—vascular cancer	0.00241	0.00241	CbGpPWpGaD
Afatinib—LCK—Immune System—CD34—vascular cancer	0.00232	0.00232	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—WWTR1—vascular cancer	0.00231	0.00231	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—WWTR1—vascular cancer	0.00222	0.00222	CbGpPWpGaD
Afatinib—ERBB2—Immune System—TSC2—vascular cancer	0.00216	0.00216	CbGpPWpGaD
Afatinib—ERBB4—Immune System—TSC2—vascular cancer	0.00213	0.00213	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—TSC2—vascular cancer	0.0021	0.0021	CbGpPWpGaD
Afatinib—BLK—Immune System—TSC2—vascular cancer	0.00205	0.00205	CbGpPWpGaD
Afatinib—ERBB2—Disease—TSC2—vascular cancer	0.00199	0.00199	CbGpPWpGaD
Afatinib—ERBB4—Disease—TSC2—vascular cancer	0.00196	0.00196	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—TSC2—vascular cancer	0.00179	0.00179	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—TSC2—vascular cancer	0.00173	0.00173	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—TSC2—vascular cancer	0.00172	0.00172	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—TSC2—vascular cancer	0.00166	0.00166	CbGpPWpGaD
Afatinib—IRAK1—Immune System—TSC2—vascular cancer	0.00156	0.00156	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—HBA1—vascular cancer	0.00144	0.00144	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TSC2—vascular cancer	0.0014	0.0014	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—WWTR1—vascular cancer	0.00139	0.00139	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TSC2—vascular cancer	0.00138	0.00138	CbGpPWpGaD
Afatinib—ABL1—Immune System—TSC2—vascular cancer	0.00122	0.00122	CbGpPWpGaD
Afatinib—EGFR—Immune System—TSC2—vascular cancer	0.00104	0.00104	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TSC2—vascular cancer	0.00101	0.00101	CbGpPWpGaD
Afatinib—LCK—Immune System—TSC2—vascular cancer	0.00101	0.00101	CbGpPWpGaD
Afatinib—EGFR—Disease—TSC2—vascular cancer	0.000964	0.000964	CbGpPWpGaD
Afatinib—LCK—Disease—TSC2—vascular cancer	0.000929	0.000929	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—HBA1—vascular cancer	0.000779	0.000779	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TSC2—vascular cancer	0.000675	0.000675	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TSC2—vascular cancer	0.00065	0.00065	CbGpPWpGaD
